- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04887571
the PrEsentation, Rationale and Impact of reperFUSION for Acute Coronary Syndromes in Cape Town and the Garden Route Health District - the PERFUSION Registry (PERFUSION)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose to set up and conduct a multi-centre, prospective, observational registry to describe the demographics, clinical characteristics, presentation, management and outcomes of patients admitted with ACS in Cape Town and the Garden Route Health District, Western Cape Province, South Africa.
The aims of this prospective multi-centre registry are to describe the burden, demographics, risk factor profile, clinical course, management, and outcomes of patients presenting with ACS across the Cape Town metropole and the Garden Route Health District. The registry will be called "the PrEsentation, Rationale and impact of reperFUSION for Acute Coronary Syndromes in Cape Town - the PERFUSION registry". It will be designed to determine the feasibility of conducting a large multi-centre Acute Coronary Syndrome registry in South Africa.
Primary Objectives:
- to enrol consecutive patients presenting with acute coronary syndromes from designated participating sites;
- to describe the demographic and risk factor profile of participants with ACS;
- to describe the burden of patients presenting with ACS in the Cape Town metropole and the Garden Route Health District;
- to describe the management of patients with ACS and assess compliance with current South African guidelines;
- to describe the one month, six-month and 12-month outcomes with regard to all-cause mortality, hospitalisation, and major adverse cardiac events (recurrence of ACS, heart failure, stroke and ventricular tachy-arrythmias).
Methods:
Registry design The PERFUSION registry will enrol consecutive consenting adults (≥ 18 years) admitted to participating healthcare centres in the cities of Cape Town and the Garden Route Health District, Western Cape, South Africa. Depending on available capacity and resources, the registry may be expanded to other healthcare centres in the Western Cape and other provinces of South Africa.
As this is fundamentally an observational study, all participants enrolled will receive management based on local standard of care guidelines. Participant management will not be affected by recruitment into this study. By using the hub/ spoke/ pre-spoke model, all patients presenting with an ACS to a designated public healthcare care facility in the Cape Town metropole and the Garden Route Health District will be screened for study eligibility criteria. Screening will occur at hub and spoke levels only. Designated site PI's will identify potential study participants meeting eligibility criteria during their index ACS admission. Once screened according to the study's inclusion and exclusion criteria, potential participants will be consented for study participation. Clinical information fulfilling pre-defined registry variables will be entered into a standardised paper-based case report form (CRF) or electronic CFR and uploaded onto a secure data collection web application called the Research Electronic Data Capture (REDCap) by the study's data capturers. Upon data entry, participants will be immediately assigned a unique identifier generated by REDCap to maintain confidentiality. The REDCap database is governed by strict password-controlled access, assigned only to approved study team members.
Data collection:
The database variables collected for this registry are in line with the American College of Cardiology Foundation / American Heart Association Task Force on Key Data Elements. These include data pertaining to patient demographics; comorbidities and prior medication; index ACS presentation at the pre-spoke, spoke or hub level; ECG features; echocardiography; laboratory investigations; management and treatment received at the pre-spoke, spoke or hub level; angiography; complications of therapies and interventions; and outcomes (in-hospital, 1 month, 6 month and 1 year).
To limit an additional burden on the healthcare system, the investigators plan on following-up participants electronically using the Western Cape Provincial Health Data Centre (PHDC) and Single Patient Viewer (SPV) online tool over a period of 1-year after the index ACS presentation. The investigators have received both HREC and provincial permission for the utilisation of data from the PHDC and SPV for this research. Follow-up data will be uploaded directly onto REDCap and anonymised.
The key outcomes of interest will include:
- mortality (all-cause and cardiovascular);
- recurrent and re-infarction myocardial infarction;
- new-onset heart failure and arrhythmia complications;
- cerebrovascular events;
- major bleeding events;
- repeat hospitalisation for any cause.
The extended list of all variables collected will be found on the registry's CRF.
Benefits of registry participation:
Although there are no direct study benefits to the participant, the study will indirectly improve our knowledge of acute coronary syndromes in South Africa. By providing local reliable evidence in our resource constraint environment, the investigators may improve the standard of care provided to patients with ACS and possibly identify novel cardioprotective strategies that may help reduce the burden of ACS in South Africa.
Risk of registry participation:
The PERFUSION registry is designed to be a prospective, observational registry. Participant enrolment will not deviate management from local standard of care guidelines. There is no investigational medicinal product, drug or device practised in this protocol. Participation in this study has no physical, psychological, social, economic or legal risk. For people who do not want to take part in the study, routine standard of care will be maintained.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7295
- Groote Schuur Hospital
-
Cape Town, Western Cape, South Africa, 7800
- Victoria Hospital
-
Cape Town, Western Cape, South Africa, 8001
- New Somerset Hospital
-
George, Western Cape, South Africa, 6529
- George Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- signed written informed consent before any study recruitment; and
- male or female patients age ≥ 18 years of age; and
- a diagnosis of ACS (STEMI, NSTEMI or UA).
Exclusion Criteria:
- ACS absent within index admission; or
- refusal of consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational ACS Registry
All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an acute coronary syndrome will be recruited into the PERFUSION registry across the study duration.
|
All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year combined primary endpoint
Time Frame: 1 year
|
all-cause death, cardiac death, re-hospitalisation myocardial infarction, cerebrovascular accident
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiac adverse events
Time Frame: 1-year
|
re-hospitalisation for heart failure, or arrhythmias
|
1-year
|
1 month combined end point
Time Frame: 1-month
|
all-cause death, cardiac death, re-hospitalisation myocardial infarction, cerebrovascular accident
|
1-month
|
6 month combined end point
Time Frame: 6-month
|
all-cause death, cardiac death, re-hospitalisation myocardial infarction, cerebrovascular accident
|
6-month
|
Compliance profile
Time Frame: 1-year
|
1-year compliance on guideline directed medical treatment
|
1-year
|
Refusion time
Time Frame: 1-year
|
Time to ECG and reperfusion in patients with Acute Coronary Syndrome
|
1-year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mpiko Ntsekhe, PhD, Groote Schuur Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Pain
- Neurologic Manifestations
- Disease
- Chest Pain
- Angina Pectoris
- Myocardial Infarction
- Infarction
- Syndrome
- ST Elevation Myocardial Infarction
- Acute Coronary Syndrome
- Angina, Unstable
- Non-ST Elevated Myocardial Infarction
Other Study ID Numbers
- PERFUSION
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on No Intervention - Observational Registry
-
Henry Ford Health SystemCompletedAcute Coronary SyndromeUnited States
-
Gulf Heart AssociationSanofi; Servier; Beshara company; Kuwait Heart FoundationRecruiting
-
Abbott Medical DevicesTerminatedMitral RegurgitationUnited States
-
Centre Hospitalier de CayenneUnknown
-
Giselle ShollerRecruiting
-
Sheba Medical CenterWithdrawn
-
Peking Union Medical College HospitalRecruitingRectal NeoplasmsChina
-
St. Louis UniversityActive, not recruitingVertebral Artery StenosisUnited States
-
Central Hospital, Nancy, FranceInstitut National de la Santé Et de la Recherche Médicale, France; University...Recruiting
-
IVAN J NUÑEZ GILCompleted